Review of Breast Abscess Management

NCT ID: NCT06225180

Last Updated: 2024-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-29

Study Completion Date

2024-06-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast abscesses are an unfortunate pathology that develop in patients, and treatment is often painful and unpleasant. The goal of this study is to identify risk factors associated with failure of aspiration as a primary intervention as opposed to incision and drainage in the hopes of adequately treating patients at initial presentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The pendulum has now swung toward minimally invasive aspiration as the primary treatment modality, with multiple studies reporting superior cosmetic results. However, patients in these studies often required repeat breast aspirations, and sometimes ultimately required incision and drainage. Aspiration first for treatment of breast abscess may not be a wise choice for all patients if it results in increased antibiotic days, return to emergency department (ED)/increased cost, or prolonged pain from multiple procedures. Several studies have identified varying risk factors for aspiration failure as primary intervention for breast abscesses. More data is needed to confirm the true risk factors for failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Abscess

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • ≥18 years of age

* New diagnosis of N61.1 recorded in their Electronic Medical Record (EMR)

Exclusion Criteria

* • \<18 years of age

* Pregnant
* Incarcerated
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Methodist Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Conner McDaniel, MD

Role: PRINCIPAL_INVESTIGATOR

Methodist Midlothian Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Institute at Methodist Health System

Dallas, Texas, United States

Site Status RECRUITING

Methodist Dallas Medical Center

Dallas, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kavya Vinod Mankulangara

Role: CONTACT

214-947-1281

Bethany Brauer, MPH

Role: CONTACT

214-947-4681

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Colette Ngo Ndjom, MS

Role: primary

410-947-4681

Colette Ngo Ndjom, MS

Role: primary

214-947-4681

Bethany Brauer, MPH

Role: backup

217-947-4680

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

021.TRA.2023.D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.